EA201590760A1 - Применение бремеланотида в терапии женской сексуальной дисфункции - Google Patents

Применение бремеланотида в терапии женской сексуальной дисфункции

Info

Publication number
EA201590760A1
EA201590760A1 EA201590760A EA201590760A EA201590760A1 EA 201590760 A1 EA201590760 A1 EA 201590760A1 EA 201590760 A EA201590760 A EA 201590760A EA 201590760 A EA201590760 A EA 201590760A EA 201590760 A1 EA201590760 A1 EA 201590760A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sexual dysfunction
bremelanotida
therapy
application
female sexual
Prior art date
Application number
EA201590760A
Other languages
English (en)
Other versions
EA032959B9 (ru
EA032959B1 (ru
Inventor
Карл Спана
Роберт Джордан
Джеффри Д. Эдельсон
Original Assignee
Палатин Текнолоджиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590760(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Палатин Текнолоджиз, Инк. filed Critical Палатин Текнолоджиз, Инк.
Publication of EA201590760A1 publication Critical patent/EA201590760A1/ru
Publication of EA032959B1 publication Critical patent/EA032959B1/ru
Publication of EA032959B9 publication Critical patent/EA032959B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Применение вводимой подкожно дозы бремеланотида или фармацевтически приемлемой соли бремеланотида, составляющей от приблизительно 1,0 до 1,75 мг, для лечения сексуальной дисфункции у женщин при уменьшении или сведении к минимуму нежелательных побочных эффектов.
EA201590760A 2012-11-05 2013-11-05 Применение бремеланотида в терапии женской сексуальной дисфункции EA032959B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (3)

Publication Number Publication Date
EA201590760A1 true EA201590760A1 (ru) 2015-10-30
EA032959B1 EA032959B1 (ru) 2019-08-30
EA032959B9 EA032959B9 (ru) 2019-11-27

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590760A EA032959B9 (ru) 2012-11-05 2013-11-05 Применение бремеланотида в терапии женской сексуальной дисфункции

Country Status (24)

Country Link
US (6) US9352013B2 (ru)
EP (1) EP2916856B2 (ru)
JP (1) JP6567971B2 (ru)
KR (1) KR102253526B1 (ru)
CN (2) CN104755094A (ru)
AU (1) AU2013337341B2 (ru)
BR (1) BR112015009936A8 (ru)
CA (1) CA2890081A1 (ru)
DK (1) DK2916856T4 (ru)
EA (1) EA032959B9 (ru)
ES (1) ES2701444T5 (ru)
FI (1) FI2916856T4 (ru)
GE (1) GEP20196947B (ru)
HK (1) HK1211227A1 (ru)
IL (1) IL238276B (ru)
MX (1) MX362610B (ru)
MY (1) MY179755A (ru)
NZ (1) NZ707246A (ru)
PH (1) PH12015500915B1 (ru)
PL (1) PL2916856T5 (ru)
SG (1) SG11201502949QA (ru)
UA (1) UA118656C2 (ru)
WO (1) WO2014071339A2 (ru)
ZA (1) ZA201503128B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) * 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1289587B1 (en) * 2000-05-31 2005-08-03 Novo Nordisk A/S A disposable double pointed injection needle
CA2453515A1 (en) 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
CN101484198A (zh) * 2004-12-09 2009-07-15 韦斯特制药服务公司 尾部装有固定针的注射器和具有该注射器的自动注射装置
WO2009120656A1 (en) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Pharmaceutical for ocular indications
MX2010013436A (es) * 2008-06-09 2011-06-21 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de disfuncion sexual.
RU2548753C2 (ru) * 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
CN104906656B (zh) * 2010-04-21 2020-01-10 艾伯维生物技术有限公司 用于治疗药剂的受控输送的可佩戴自动注射装置

Also Published As

Publication number Publication date
CN117860866A (zh) 2024-04-12
MX2015005486A (es) 2015-11-13
ZA201503128B (en) 2016-11-30
EP2916856A4 (en) 2016-06-22
EP2916856B2 (en) 2023-10-18
US10286034B2 (en) 2019-05-14
PH12015500915A1 (en) 2015-06-29
US20140378392A1 (en) 2014-12-25
DK2916856T3 (en) 2019-01-14
MY179755A (en) 2020-11-12
SG11201502949QA (en) 2015-06-29
NZ707246A (en) 2019-03-29
KR102253526B1 (ko) 2021-05-18
US20150231196A1 (en) 2015-08-20
EA032959B9 (ru) 2019-11-27
US9352013B2 (en) 2016-05-31
FI2916856T4 (fi) 2024-01-15
US20210060120A1 (en) 2021-03-04
AU2013337341A1 (en) 2015-05-07
EA032959B1 (ru) 2019-08-30
PL2916856T3 (pl) 2019-02-28
DK2916856T4 (da) 2024-01-22
PL2916856T5 (pl) 2024-01-29
ES2701444T5 (es) 2024-05-21
WO2014071339A3 (en) 2014-06-12
UA118656C2 (uk) 2019-02-25
KR20150081345A (ko) 2015-07-13
PH12015500915B1 (en) 2015-06-29
MX362610B (es) 2019-01-28
EP2916856B1 (en) 2018-09-19
US20190216888A1 (en) 2019-07-18
US20220362328A1 (en) 2022-11-17
GEP20196947B (en) 2019-02-11
IL238276A0 (en) 2015-06-30
BR112015009936A8 (pt) 2019-09-17
CA2890081A1 (en) 2014-05-08
IL238276B (en) 2020-04-30
JP6567971B2 (ja) 2019-08-28
US9700592B2 (en) 2017-07-11
AU2013337341B2 (en) 2018-02-22
ES2701444T3 (es) 2019-02-22
BR112015009936A2 (pt) 2017-07-11
CN104755094A (zh) 2015-07-01
WO2014071339A2 (en) 2014-05-08
US20180085425A1 (en) 2018-03-29
EP2916856A2 (en) 2015-09-16
JP2016503406A (ja) 2016-02-04
HK1211227A1 (en) 2016-05-20

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
NZ714963A (en) Compositions and methods for treating anemia
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NZ732507A (en) Improved compositions for treating muscular dystrophy
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
MX2021014523A (es) Metodos para tratar colangiocarcinoma.
PH12017500617A1 (en) Dosage regimen for pegylated interferon
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2021005876A (es) Elacestrant en combinacion con abemaciclib en mujeres con cancer de mama.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
MX2018001528A (es) Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña.
NZ599227A (en) Therapeutic agent for chronic pain
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM